• 环球360

    A Global Innovation-driven Pharmaceutical
    and Healthcare Industry Group
    • 410,67 Million
      FY2024 Revenue
    • 2,770 Million
      FY2024 Net Profit Attributable to Shareholders
    • 5,554 Million
      FY2024 R&D Expenditure
    • 40,557
      Global Employees
    • A
      MSCI ESG Rating
    As of December 31, 2024
    Unit: RMB million

    • Artesun® (Artesunate for Injection)

      The WHO-recommended First-line Treatment of Severe Malaria

      By the end of 2022, Fosun Pharma's self-developed antimalarial innovative drug Artesun® (Artesunate for Injection) had helped more than 56 million patients with severe malaria worldwide.

    • Han Li Kang (Rituximab Injection)

      First China-developed Biosimilar

      Since its approval in 2019, Han Li Kang has benefited more than 100,000 patients in China

    • Han Qu You(trastuzumab, Zercepac® in the EU)

      The first China-developed mAb biosimilar approved both in China and in the EU

      Zercepac®（150mg）has been marketed in nearly 20 EU countries and regions such as England, Germany, Spain and France.

    • Han Si Zhuang （Serplulimab Injection）

      Henlius’s first self-developed innovative monoclonal antibody approved by the NMPA

    • Yi Kai Da (Axicabtagene Ciloleucel)

      China's first approved CAR-T cell therapy

      As of the end of 2022, Yi Kai Da has been included in the urban customized commercial health insurance of 70 provinces and municipalities and over 60 commercial insurances, while the number of treatment centers on record ~exceeded 130. As of the end of January 2023, nearly 300 patients with relapsed or refractory large B-cell lymphoma lymphoma had been treated with Yi Kai Da.

    • Su Ke Xin (Avatrombopag Maleate Tablets)

      Fosun Pharma’s first innovative small molecule drug introduced and China’s first drug approved for CLDT treatment

      Su Ke Xin was included in the national medical insurance catalog in December 2020, and the medical insurance standard has been implemented from March 1, 2021, which comprehensively improves the accessibility of clinical treatment for patients

    • mRNA COVID-19 Vaccine COMIRNATY® (also known as BNT162b2)

      Both the monovalent COVID-19 vaccine COMIRNATY (30 mg per dose) (also known as BNT162b2 or COMIRNATY Original) and COMIRNATY Original/Omicron BA.4/BA.5 bivalent COVID-19 vaccine (also known as COMIRNATY Bivalent COVID-19 Vaccine) were officially registered in Hong Kong SAR and approved as a regular imported vaccine by the Macao SAR., fully covering the public and private markets.

    • Novel Coronavirus (2019-nCoV) Antigen Detection Kit and Novel Coronavirus (2019-nCoV) RT-PCR Detection Kit

      Fosun Diagnostics is one of the dual-certificate enterprises that have obtained the registration certificates of both Novel Coronavirus Antigen Detection Kit and Novel Coronavirus RT-PCR Detection Kit

    • Da Vinci Surgical Robots

      The first robotic surgery system approved by the FDA for general laparoscopic surgery and the most widely used laparoscopic surgery robot in the world

    • Pharmaceutical Manufacturing

    • Vaccines

    • Medical Devices

    • Medical Diagnosis

    • Healthcare Services

    • Pharmaceutical Distribution And Retail

    Stock Quote

    Dual-Listed on A+H Shares

    Sustainable Development

    In Pursuit of Sustainable Development of Talents and Products

    Fosun Pharma adheres to the concept of "pursuing sustainable development of talents and products", comprehensively practices corporate social responsibility, continuously improves the satisfaction of stakeholders, and is committed to leading the development of social responsibility in the industry.